D.C. Council waters down I-82, affecting local restaurants
Why it matters: The city has struggled with I-82's implementation for years. The new measure aims to balance working wages with business survival — especially for independent D.C. restaurants, which are struggling.
Driving the news: Eliminating the tipped minimum wage — as the original ballot measure promised — is off the table. Instead, the I-82 amendment introduced by Council members Christina Henderson and Charles Allen preserves the tipped minimum wage and stretches base wage hikes over the next decade at a fraction of the standard minimum wage (currently $17.95/hour).
The measure passed 7-5 during a tense hearing that began with protestor interruptions and ended with a lockdown of council chambers as protestors shouted and banged on doors.
📅 New timeline: Now through July 2026, a $10/hour tipped wage (56% of regular minimum wage).
That'll increase every two years, capping off at 75% of the minimum wage in 2034.
Catch up quick: The hospitality industry struggled to adjust to I-82. Many cited skyrocketing labor costs that coincided with inflation, rising rents and plummeting patronage due to mass DMV layoffs. Workers complained of diminished tips, especially as businesses implemented service fees to cover costs.
Meanwhile, the city has been inconsistent with I-82's rollout. Mayor Muriel Bowser recently pushed for a full repeal, which the council voted down.
Friction point: Tempers in the council chambers ran high as I-82 supporters chanted, "Blood is on your hands." After the vote, the Restaurant Association of Metropolitan Washington hailed the decision as a "win for the industry," one that "brings immediate relief to operators" in a statement sent to Axios.
One Fair Wage, the primary lobby behind I-82, called it a "betrayal of democracy and a gift to the restaurant lobby" in another statement.
Meanwhile, there was concern over going against voters' will. "The voters told us what they wanted. And this is not it," said Council member Brianne Nadeau, who voted against the amendment. "This council should stop telling voters they don't know what's best."
How they voted:
✔️ For the amendment: Charles Allen, Christina Henderson, Brooke Pinto, Phil Mendelson, Kenyan McDuffie, Wendell Felder, Anita Bonds
❌ Against: Brianne Nadeau, Janeese Lewis George, Robert White, Matt Frumin, Zachary Parker
What's next: The amendment aims to provide more wage transparency. Starting in 2026, pay stubs must list all sources — including tips, bonuses, service charges, etc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
3 hours ago
- The Hill
Trump trails Ocasio-Cortez, Sanders in favorability polling: Gallup
President Trump trails progressive stalwarts Rep. Alexandria Ocasio-Cortez (D-N.Y.) and Sen. Bernie Sanders (I-Vt.) in favorability polling, according to a new survey conducted by Gallup. The poll, which was released Tuesday morning, found that among 14 prominent figures, Trump's net favorable rating was minus 16 points, with 41 percent of respondents having a favorable view of the president, while 57 percent said the opposite. Some two percent had no opinion about the president. Ocasio-Cortez's net favorability was minus four points, with 34 percent having a favorable view of the progressive firebrand, while another 38 percent had an unfavorable outlook on the New York Democrat. About 28 percent had no opinion about the progressive lawmaker. Former President Biden, whose public support while in office never recovered after dropping midway through his Oval Office term, accumulated a minus 11 point favorable rating, placing him in the middle of the list. Around 43 percent of U.S. adults had a favorable view of Biden, while 54 percent said the opposite. Some three percent had no opinion. Pope Leo XIV had the most positive image out of the 14 public figures on the list, with 57 percent having a favorable view and just 11 percent going in the opposite. Nearly a third, 31 percent, had no opinion about the American-born pontiff. Second on the list was Ukrainian President Volodymyr Zelensky with plus 18, while in third place was Sanders with plus 11, the survey found. California Gov. Gavin Newsom (D) and Vice President Vance had an identical net favorability with minus 11 points. Among Trump administration officials, the favorability has dropped the most for Secretary of State Marco Rubio and tech billionaire Elon Musk, with each dropping by 24 points, Gallup noted. Rubio's net favorability is at minus 16 points, with 31 percent having a favorable view of the former Florida senator, while 47 percent have an unfavorable outlook. Musk, the former head of the Department of Government Efficiency who had a public fallout with Trump over the president's signature 'Big, Beautiful Bill,' was at the bottom of the list with minus 28 net favorability, a 24-point downward swing since January. Gallup noted that the 'dampened favorable ratings of key Trump administration officials since January are broadly consistent with the decline in Trump's job approval rating over the same period, down 10 percentage points.' A late July Gallup poll found that Trump's approval rating was at 37 percent, down 10 points since taking office. The recent The Economist/YouGov survey found the president's net approval rating to be 15 points underwater. The poll was conducted from July 7-21 among 1,002 adults. The margin of error was four percentage points at the 95 percent confidence level.
Newsweek
4 hours ago
- Newsweek
Donald Trump's Approval Rating Jumps With Liberals
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump's approval rating has increased among liberals in the past month. According to polling by I&I/TIPP released on August 4, the proportion of liberals who said they approved of Trump's job performance increased by 4 percentage points from 19 percent at the end of June to 23 percent in early August. Why It Matters Approval ratings are a good way of measuring the temperature of the nation and Trump's popularity has fluctuated in the first six-plus months of his term in the Oval Office. Liberals do not generally have a positive view of the president or his policies so an uptick in approval rating is noteworthy. It remains to be seen whether this will sustain and ultimately affect the 2026 midterm elections. President Donald Trump speaks with reporters before boarding Air Force One at Lehigh Valley International Airport, Sunday, Aug. 3, 2025, in Allentown, Pa. President Donald Trump speaks with reporters before boarding Air Force One at Lehigh Valley International Airport, Sunday, Aug. 3, 2025, in Allentown, Pa. AP Photo/Julia Demaree Nikhinson What To Know While the proportion of liberals who said they approved of Trump has increased, the majority of liberals (72 percent) still see him in an unfavorable light. The proportion of liberals with a favorable view of the president increased from 18 percent at the end of June to 23 percent in August—an increase of 5 percentage points. Overall, Trump's favorability rating among all voters was net -1 percent in July and net 0 percent in August. The June poll was conducted between June 25 and 27 had a sample size of 1,421 adults. In August, 1,362 adults were polled from July 30 to August 1. Both polls had a margin of error of +/- 2.7 percentage points. Polling elsewhere has been less positive. A survey conducted by Quantus Insights from July 21 to July 23 among 1,123 registered voters showed his rating stands at 47 percent, while 50 percent disapproved. According to the YouGov polling for British newspaper The Times, the proportion of people who disapprove of Trump's job performance has increased from 52 percent in April to 57 percent in July. What People Are Saying Speaking to Newsweek, Mark Shanahan, who teaches American politics at the University of Surrey in the U.K, previously said: "Trump's second term has been less of a honeymoon, but more of a divorce from half the country: one where he's got to keep the house, the kids and just about all of the assets. From day one of his rule by Executive Order he has never sought to bring the USA together and, indeed, has exploited differences to highlight how he's delivering on his campaign commitments, not least through DOGE [Department of Government Efficiency], through his clampdown on immigration and through his America First foreign policy." "Public services are already beginning to creak thanks to the actions of Musk and his cohort, and tariffs are driving up prices at home, while the economic benefits of the One Big Beautiful act have yet to be felt. And around all this, the whiff of Epstein is tainting the president's achievements." What Happens Next The midterms are scheduled to take place in November 2026 where Trump's popularity will be tested in earnest.
Yahoo
5 hours ago
- Yahoo
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025 UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and Europe PS-002, Purespring's lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical data London – 5 August 2025 - Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that its UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002, Purespring's lead programme, in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC). 'The CTA approval for our Phase I/II clinical trial of PS-002 represents another key milestone as we complete our transition to a clinical-stage precision nephrology company,' said Haseeb Ahmad, Purespring's Chief Executive Officer. 'Building on the recent FDA IND clearance and EMA orphan drug designation, this further validates the potential of our podocyte-targeting approach to go beyond symptom management and directly target kidney disease at its source. Looking ahead, we are committed to working closely with regulators and sites across the U.S. and Europe with the view to expand the therapeutic options available for people living with IgAN.' PS-002 was developed to target the underlying cause of many kidney diseases by modulating complement activation in the kidney via precision targeting of podocytes. The programme is initially focused on the treatment of IgA nephropathy (IgAN), a rare and chronic autoimmune kidney disease that primarily affects young adults. In IgAN, aberrant immunoglobin A (IgA) protein becomes trapped in the kidney's filters, known as the glomeruli, causing complement activation, inflammation, damage and scarring. A significant proportion of affected patients will go on to develop kidney failure despite currently available therapies. The Phase I/II clinical trial, which is expected to enroll its first patient in Q4 2025, will evaluate local administration of PS-002 to treat IgAN. In the Phase 1 part of the Phase I/II study, the main read-outs will be safety parameters, which, together with efficacy biomarkers, will be leveraged to select a dose for the Phase 2 part of the study. This second phase will be used to further define the safety profile and provide early markers of efficacy. Enabled by this latest regulatory approval and the recent U.S. IND clearance, as announced in July 2025, the Phase I/II study will recruit patients across the U.S. and Europe. For further information, contact: Purespring: Peter Mulcahycontact@ (0)20 3855 6324LinkedIn ICR Healthcare Amber Fennell, Sarah Elton-Farrpurespring@ Notes to Editors About Purespring Purespring is developing therapies to halt or prevent kidney disease, one of humankind's most poorly treated disease areas. Founded on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, Purespring is the first company to successfully treat kidney disease by targeting the podocyte, a specialised cell that is implicated in the majority of renal disease. Purespring's platform approach enables streamlined gene therapy development for both acquired and genetic renal diseases, offering the potential to halt, reverse and even cure both rare and common kidney diseases. The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has programmes for disease caused by mutations in the gene NPHS2, as well as other monogenic glomerular kidney diseases. Based in London, the Purespring team combines world-leading expertise in podocyte biology and kidney disease with a wealth of experience in gene therapies, anchored in a culture of diversity, creativity and delivery. Purespring is backed by leading biotech investors, including Syncona Limited, Sofinnova Partners, Gilde Healthcare, Forbion, and the British Business Bank and has raised £115m ($149m) to date. For more information please visit: and follow us on LinkedIn.
